Mirvetuximab soravtansine, sold under the brand name Elahere, is a medication used as a treatment for fallopian tube cancer or primary peritoneal cancer. Mirvetuximab soravtansine is a folate receptor alpha directed antibody and microtubule inhibitor conjugate. Mirvetuximab soravtansine was approved for medical use in the United States in November 2022.
Attributes | Values |
---|---|
rdf:type | |
rdfs:label |
|
rdfs:comment |
|
foaf:depiction | |
dcterms:subject | |
Wikipage page ID |
|
Wikipage revision ID |
|
Link from a Wikipage to another Wikipage | |
Link from a Wikipage to an external page | |
sameAs | |
dbp:wikiPageUsesTemplate | |
thumbnail | |
ATC prefix |
|
CAS number |
|
KEGG |
|
legal US |
|
routes of administration | |
source |
|
synonyms |
|
target |
|
tradename |
|
type |
|
UNII |
|
width |
|
has abstract |
|
DailyMedID |
|
mab type |
|
prov:wasDerivedFrom | |
page length (characters) of wiki page |
|
alternative name |
|
CAS number |
|
FDA UNII code |
|
KEGG |
|
foaf:isPrimaryTopicOf | |
is Link from a Wikipage to another Wikipage of | |
is Wikipage redirect of | |
is foaf:primaryTopic of |